Table 1.
Characteristics of the Study Population at the Time of the Baseline Study Visit
| AF Med Mx (n=58) | AF Ablation (n=20) | P Value | Overall (n=78) | |
|---|---|---|---|---|
| Age, y | 60±10 | 57±13 | 0.242 | 59±10 |
| Male, n (%) | 43 (74) | 15 (75) | 0.323 | 58 (74) |
| BMI, kg/m2 | 30.1±5.7 | 29.2±3.7 | 0.519 | 29.9±5.2 |
| Hypertension, n (%) | 28 (48) | 8 (40) | 0.524 | 36 (46) |
| Diabetes mellitus, n (%) | 11 (19) | 2 (10) | 0.263 | 13 (17) |
| Stroke/TIA, n (%) | 4 (7) | 1 (5) | 0.768 | 5 (6) |
| Vascular disease, n (%) | 12 (21) | 4 (20) | 0.948 | 16 (21) |
| OSA, n (%) | 12 (21) | 4 (20) | 0.954 | 16 (21) |
| CHA2DS2Vasc | 1 (0–3) | 1 (0–2) | 0.691 | 1 (0–3) |
| E/E′ | 8.6±3.0 | 7.3±1.9 | 0.089 | 8.3±2.8 |
| LA volume, mL/m2 | 47.5±16.5 | 46.3±11.0 | 0.761 | 47.2±15.2 |
| Peak positive LA strain rate, s−1 | 1.02±0.36 | 0.98±0.21 | 0.681 | 1.0±0.3 |
| Chronic anticoagulation, n (%) | 32 (55) | 13 (65) | 0.671 | 45 (58) |
| β‐blocker, n (%) | 20 (34) | 7 (35) | 0.967 | 27 (35) |
| Calcium‐channel blocker, n (%) | 7 (12) | 2 (10) | 0.804 | 9 (12) |
| Digoxin, n (%) | 15 (26) | 4 (20) | 0.601 | 19 (24) |
| Flecainide, n (%) | 11 (19)a | 2 (10) | 0.357 | 13 (17) |
| Sotalol, n (%) | 15 (26)b | 10 (50) | 0.047 | 25 (32) |
AF indicates atrial fibrillation; BMI, body mass index; LA, left atrium; OSA, obstructive sleep apnea; TIA, transient ischemic attack.
a
Increased to 31% by 12‐month study visit.
b
Increased to 39% by 12‐month study visit.